Share Price and Basic Stock Data
Last Updated: January 17, 2026, 6:32 am
| PEG Ratio | 0.34 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bliss GVS Pharma Ltd operates within the pharmaceuticals sector, with its stock price recently reported at ₹164 and a market capitalization of ₹1,735 Cr. The company has demonstrated fluctuations in revenue, recording sales of ₹752 Cr for the fiscal year ending March 2023, which increased to ₹770 Cr for March 2024, and is projected to reach ₹810 Cr in March 2025. Quarterly sales figures have also shown variability, with a peak of ₹218 Cr in September 2024, while the most recent quarter reported ₹201 Cr in December 2024. Notably, the company’s operating profit margin (OPM) has varied, peaking at 26% in September 2023, reflecting strong efficiency in managing costs. Overall, Bliss GVS Pharma’s revenue trajectory indicates a modest growth pattern, albeit with some quarter-to-quarter volatility, typical for companies in the pharmaceuticals space due to regulatory and market dynamics.
Profitability and Efficiency Metrics
Bliss GVS Pharma’s profitability metrics indicate a mixed performance. The company reported a net profit of ₹115 Cr for the trailing twelve months, translating to an earnings per share (EPS) of ₹8.02. The return on equity (ROE) stood at 8.36%, while the return on capital employed (ROCE) was recorded at 11.7%. The operating profit margin hovered around 13% for the most recent fiscal year. Efficiency ratios revealed a cash conversion cycle (CCC) of 246 days, which is relatively high compared to industry standards, indicating potential issues in working capital management. Interest coverage ratio (ICR) was robust at 20.10x, suggesting strong capacity to meet interest obligations. While the company has effectively maintained a positive EPS trend, the profitability margins suggest room for improvement, particularly in managing operational costs and enhancing efficiency.
Balance Sheet Strength and Financial Ratios
Bliss GVS Pharma’s balance sheet reflects a solid foundation with total assets amounting to ₹1,400 Cr as of September 2025. The company reported reserves of ₹1,122 Cr, which provides a cushion for future investments and operational needs. Borrowings stood at ₹52 Cr, indicating a low debt load and a total debt-to-equity ratio of 0.06, which is favorable compared to industry norms. The current ratio of 4.81x and quick ratio of 4.08x signify a strong liquidity position, suggesting the company can easily meet its short-term obligations. The price-to-book value (P/BV) ratio of 1.18x indicates that the stock is trading at a reasonable valuation compared to its book value, reflecting investor confidence in the company’s financial health. Overall, Bliss GVS Pharma’s balance sheet metrics demonstrate strong stability and prudent financial management.
Shareholding Pattern and Investor Confidence
The shareholding structure of Bliss GVS Pharma indicates a diversified ownership base, with promoters holding 35.39% of the company as of September 2025. Foreign institutional investors (FIIs) accounted for 13.27%, while domestic institutional investors (DIIs) held 5.98%. The public ownership stood at 45.36%, with a total of 44,461 shareholders, reflecting a robust retail participation. Over the past year, promoter holdings have remained stable, suggesting confidence in the company’s strategic direction. However, FII holdings have shown a declining trend from 16.53% in December 2022 to the current level, which may indicate some caution among foreign investors. The stability in promoter holdings combined with a high public stake suggests a balanced investor sentiment, although the decline in FII interest could be a point of concern for future capital inflow.
Outlook, Risks, and Final Insight
Bliss GVS Pharma faces both opportunities and challenges ahead. The company’s consistent revenue growth and strong balance sheet position it well for future expansion, particularly in light of the increasing demand for pharmaceuticals. However, risks such as high operating expenses and a prolonged cash conversion cycle could hinder profitability. Additionally, regulatory changes and market competition pose potential threats to maintaining market share. To navigate these challenges, the company may need to focus on improving operational efficiency and exploring new markets. Should Bliss GVS Pharma successfully enhance its margins and manage its working capital more effectively, it could see significant upside. Conversely, failure to address these operational challenges could pressure profitability and investor sentiment in the long term.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,986.97 Cr | 1,115.98 | 52.27 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 172 | 206 | 185 | 160 | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 |
| Expenses | 148 | 158 | 179 | 135 | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 213 |
| Operating Profit | 25 | 48 | 6 | 24 | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 | 32 |
| OPM % | 14% | 23% | 3% | 15% | 26% | 22% | 14% | 19% | 19% | 14% | 11% | 20% | 13% |
| Other Income | 2 | 6 | 3 | 5 | 13 | 5 | -24 | 4 | 5 | 15 | 12 | 35 | 20 |
| Interest | 2 | 1 | 5 | 1 | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 |
| Depreciation | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 |
| Profit before tax | 20 | 47 | -1 | 22 | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 |
| Tax % | 21% | 37% | -561% | 34% | 27% | 27% | 24% | 26% | 28% | 29% | 29% | 30% | 30% |
| Net Profit | 16 | 30 | 3 | 14 | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 |
| EPS in Rs | 1.33 | 2.68 | 0.32 | 1.41 | 4.05 | 2.64 | -0.87 | 1.97 | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 |
Last Updated: January 2, 2026, 5:32 am
Below is a detailed analysis of the quarterly data for Bliss GVS Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 244.00 Cr.. The value appears strong and on an upward trend. It has increased from 207.00 Cr. (Jun 2025) to 244.00 Cr., marking an increase of 37.00 Cr..
- For Expenses, as of Sep 2025, the value is 213.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 166.00 Cr. (Jun 2025) to 213.00 Cr., marking an increase of 47.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Jun 2025) to 32.00 Cr., marking a decrease of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 13.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Jun 2025) to 13.00%, marking a decrease of 7.00%.
- For Other Income, as of Sep 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 35.00 Cr. (Jun 2025) to 20.00 Cr., marking a decrease of 15.00 Cr..
- For Interest, as of Sep 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 8.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 41.00 Cr.. The value appears to be declining and may need further review. It has decreased from 63.00 Cr. (Jun 2025) to 41.00 Cr., marking a decrease of 22.00 Cr..
- For Tax %, as of Sep 2025, the value is 30.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 30.00%.
- For Net Profit, as of Sep 2025, the value is 29.00 Cr.. The value appears to be declining and may need further review. It has decreased from 44.00 Cr. (Jun 2025) to 29.00 Cr., marking a decrease of 15.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.58. The value appears to be declining and may need further review. It has decreased from 4.08 (Jun 2025) to 2.58, marking a decrease of 1.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:33 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 345 | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 860 |
| Expenses | 273 | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 634 | 620 | 683 | 736 |
| Operating Profit | 71 | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 | 124 |
| OPM % | 21% | 25% | 29% | 25% | 24% | 18% | 18% | 18% | 16% | 16% | 20% | 16% | 14% |
| Other Income | 28 | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 18 | -0 | 36 | 83 |
| Interest | 18 | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 10 | 7 | 8 | 11 |
| Depreciation | 11 | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 32 |
| Profit before tax | 71 | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 164 |
| Tax % | 42% | 36% | 32% | 36% | 39% | 30% | 26% | 29% | 57% | 28% | 30% | 28% | |
| Net Profit | 41 | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 115 |
| EPS in Rs | 3.97 | 5.81 | 8.00 | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 | 10.39 |
| Dividend Payout % | 13% | 12% | 6% | 8% | 18% | 8% | 5% | 8% | 34% | 7% | 7% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 48.78% | 63.93% | 13.00% | -21.24% | 42.70% | -25.20% | -22.11% | -68.92% | 234.78% | 6.49% | 9.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | 15.15% | -50.93% | -34.24% | 63.94% | -67.89% | 3.09% | -46.81% | 303.70% | -228.29% | 3.26% |
Bliss GVS Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 3% |
| 3 Years: | 3% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -5% |
| 3 Years: | 44% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 1% |
| 3 Years: | 24% |
| 1 Year: | 22% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 8% |
| 3 Years: | 9% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 1:05 am
Balance Sheet
Last Updated: December 4, 2025, 1:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 |
| Reserves | 277 | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 | 1,040 | 1,122 |
| Borrowings | 173 | 160 | 132 | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | 88 | 52 |
| Other Liabilities | 123 | 166 | 218 | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 145 | 162 | 215 |
| Total Liabilities | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,400 |
| Fixed Assets | 213 | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | 406 | 392 |
| CWIP | 4 | 0 | 9 | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 | 21 | 39 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 | 10 |
| Other Assets | 365 | 428 | 527 | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 830 | 870 | 959 |
| Total Assets | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,400 |
Below is a detailed analysis of the balance sheet data for Bliss GVS Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,122.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,040.00 Cr. (Mar 2025) to 1,122.00 Cr., marking an increase of 82.00 Cr..
- For Borrowings, as of Sep 2025, the value is 52.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 88.00 Cr. (Mar 2025) to 52.00 Cr., marking a decrease of 36.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 215.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 162.00 Cr. (Mar 2025) to 215.00 Cr., marking an increase of 53.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,400.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,301.00 Cr. (Mar 2025) to 1,400.00 Cr., marking an increase of 99.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 392.00 Cr.. The value appears to be declining and may need further review. It has decreased from 406.00 Cr. (Mar 2025) to 392.00 Cr., marking a decrease of 14.00 Cr..
- For CWIP, as of Sep 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 18.00 Cr..
- For Investments, as of Sep 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 10.00 Cr., marking an increase of 6.00 Cr..
- For Other Assets, as of Sep 2025, the value is 959.00 Cr.. The value appears strong and on an upward trend. It has increased from 870.00 Cr. (Mar 2025) to 959.00 Cr., marking an increase of 89.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,400.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,301.00 Cr. (Mar 2025) to 1,400.00 Cr., marking an increase of 99.00 Cr..
Notably, the Reserves (1,122.00 Cr.) exceed the Borrowings (52.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -102.00 | -57.00 | 24.00 | -22.00 | 79.00 | 58.00 | -3.00 | -15.00 | 9.00 | 15.00 | 51.00 | 39.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 228 | 222 | 201 | 116 | 134 | 187 | 290 | 293 | 192 | 187 | 192 | 198 |
| Inventory Days | 70 | 69 | 55 | 50 | 55 | 46 | 64 | 110 | 116 | 94 | 113 | 111 |
| Days Payable | 176 | 165 | 153 | 100 | 55 | 47 | 75 | 82 | 86 | 79 | 58 | 63 |
| Cash Conversion Cycle | 121 | 126 | 102 | 67 | 134 | 186 | 279 | 321 | 221 | 202 | 247 | 246 |
| Working Capital Days | 86 | 105 | 84 | -10 | 135 | 154 | 232 | 264 | 179 | 192 | 207 | 199 |
| ROCE % | 20% | 23% | 31% | 29% | 27% | 26% | 18% | 12% | 14% | 12% | 14% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 669 | 0.07 | 0.01 | 669 | 2025-04-22 17:25:40 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.02 | 7.23 | 6.83 | 1.46 | 6.64 |
| Diluted EPS (Rs.) | 7.95 | 7.11 | 6.72 | 1.43 | 6.49 |
| Cash EPS (Rs.) | 11.36 | 10.31 | 9.16 | 3.90 | 8.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 99.68 | 95.80 | 88.08 | 81.64 | 80.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 99.68 | 95.80 | 88.08 | 81.64 | 80.27 |
| Revenue From Operations / Share (Rs.) | 76.85 | 73.57 | 72.16 | 72.09 | 55.96 |
| PBDIT / Share (Rs.) | 15.49 | 17.13 | 12.97 | 14.45 | 12.30 |
| PBIT / Share (Rs.) | 12.69 | 14.61 | 11.18 | 12.78 | 10.63 |
| PBT / Share (Rs.) | 11.92 | 11.16 | 10.18 | 5.22 | 10.10 |
| Net Profit / Share (Rs.) | 8.57 | 7.79 | 7.37 | 2.23 | 7.17 |
| NP After MI And SOA / Share (Rs.) | 8.00 | 7.21 | 6.80 | 1.45 | 6.64 |
| PBDIT Margin (%) | 20.15 | 23.28 | 17.97 | 20.04 | 21.98 |
| PBIT Margin (%) | 16.51 | 19.86 | 15.49 | 17.72 | 18.99 |
| PBT Margin (%) | 15.51 | 15.17 | 14.11 | 7.24 | 18.03 |
| Net Profit Margin (%) | 11.14 | 10.59 | 10.20 | 3.09 | 12.81 |
| NP After MI And SOA Margin (%) | 10.41 | 9.79 | 9.42 | 2.01 | 11.86 |
| Return on Networth / Equity (%) | 8.02 | 7.80 | 8.01 | 1.83 | 8.47 |
| Return on Capital Employeed (%) | 11.84 | 14.51 | 12.08 | 15.13 | 12.55 |
| Return On Assets (%) | 6.48 | 6.21 | 6.12 | 1.35 | 6.36 |
| Long Term Debt / Equity (X) | 0.01 | 0.03 | 0.04 | 0.02 | 0.04 |
| Total Debt / Equity (X) | 0.06 | 0.09 | 0.11 | 0.12 | 0.12 |
| Asset Turnover Ratio (%) | 0.64 | 0.64 | 0.53 | 0.59 | 0.47 |
| Current Ratio (X) | 4.81 | 5.08 | 3.61 | 3.33 | 3.76 |
| Quick Ratio (X) | 4.08 | 4.34 | 3.08 | 2.80 | 3.27 |
| Inventory Turnover Ratio (X) | 6.63 | 3.06 | 2.96 | 3.71 | 2.73 |
| Dividend Payout Ratio (NP) (%) | 6.22 | 6.90 | 7.32 | 34.41 | 7.52 |
| Dividend Payout Ratio (CP) (%) | 4.61 | 5.11 | 5.79 | 15.98 | 6.01 |
| Earning Retention Ratio (%) | 93.78 | 93.10 | 92.68 | 65.59 | 92.48 |
| Cash Earning Retention Ratio (%) | 95.39 | 94.89 | 94.21 | 84.02 | 93.99 |
| Interest Coverage Ratio (X) | 20.10 | 25.95 | 13.04 | 31.60 | 23.01 |
| Interest Coverage Ratio (Post Tax) (X) | 12.12 | 17.03 | 8.40 | 21.40 | 14.42 |
| Enterprise Value (Cr.) | 1137.76 | 1087.33 | 770.70 | 752.99 | 990.81 |
| EV / Net Operating Revenue (X) | 1.41 | 1.41 | 1.03 | 1.01 | 1.72 |
| EV / EBITDA (X) | 6.97 | 6.06 | 5.70 | 5.03 | 7.81 |
| MarketCap / Net Operating Revenue (X) | 1.53 | 1.53 | 0.98 | 1.07 | 1.76 |
| Retention Ratios (%) | 93.77 | 93.09 | 92.67 | 65.58 | 92.47 |
| Price / BV (X) | 1.18 | 1.22 | 0.83 | 0.97 | 1.26 |
| Price / Net Operating Revenue (X) | 1.53 | 1.53 | 0.98 | 1.07 | 1.76 |
| EarningsYield | 0.06 | 0.06 | 0.09 | 0.01 | 0.06 |
After reviewing the key financial ratios for Bliss GVS Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.02. This value is within the healthy range. It has increased from 7.23 (Mar 24) to 8.02, marking an increase of 0.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.95. This value is within the healthy range. It has increased from 7.11 (Mar 24) to 7.95, marking an increase of 0.84.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.36. This value is within the healthy range. It has increased from 10.31 (Mar 24) to 11.36, marking an increase of 1.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 99.68. It has increased from 95.80 (Mar 24) to 99.68, marking an increase of 3.88.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 99.68. It has increased from 95.80 (Mar 24) to 99.68, marking an increase of 3.88.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 76.85. It has increased from 73.57 (Mar 24) to 76.85, marking an increase of 3.28.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.49. This value is within the healthy range. It has decreased from 17.13 (Mar 24) to 15.49, marking a decrease of 1.64.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 14.61 (Mar 24) to 12.69, marking a decrease of 1.92.
- For PBT / Share (Rs.), as of Mar 25, the value is 11.92. This value is within the healthy range. It has increased from 11.16 (Mar 24) to 11.92, marking an increase of 0.76.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 7.79 (Mar 24) to 8.57, marking an increase of 0.78.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.00. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 8.00, marking an increase of 0.79.
- For PBDIT Margin (%), as of Mar 25, the value is 20.15. This value is within the healthy range. It has decreased from 23.28 (Mar 24) to 20.15, marking a decrease of 3.13.
- For PBIT Margin (%), as of Mar 25, the value is 16.51. This value is within the healthy range. It has decreased from 19.86 (Mar 24) to 16.51, marking a decrease of 3.35.
- For PBT Margin (%), as of Mar 25, the value is 15.51. This value is within the healthy range. It has increased from 15.17 (Mar 24) to 15.51, marking an increase of 0.34.
- For Net Profit Margin (%), as of Mar 25, the value is 11.14. This value exceeds the healthy maximum of 10. It has increased from 10.59 (Mar 24) to 11.14, marking an increase of 0.55.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.41. This value is within the healthy range. It has increased from 9.79 (Mar 24) to 10.41, marking an increase of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.02. This value is below the healthy minimum of 15. It has increased from 7.80 (Mar 24) to 8.02, marking an increase of 0.22.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.84. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.84, marking a decrease of 2.67.
- For Return On Assets (%), as of Mar 25, the value is 6.48. This value is within the healthy range. It has increased from 6.21 (Mar 24) to 6.48, marking an increase of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. There is no change compared to the previous period (Mar 24) which recorded 0.64.
- For Current Ratio (X), as of Mar 25, the value is 4.81. This value exceeds the healthy maximum of 3. It has decreased from 5.08 (Mar 24) to 4.81, marking a decrease of 0.27.
- For Quick Ratio (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 2. It has decreased from 4.34 (Mar 24) to 4.08, marking a decrease of 0.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.63. This value is within the healthy range. It has increased from 3.06 (Mar 24) to 6.63, marking an increase of 3.57.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.22. This value is below the healthy minimum of 20. It has decreased from 6.90 (Mar 24) to 6.22, marking a decrease of 0.68.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.61. This value is below the healthy minimum of 20. It has decreased from 5.11 (Mar 24) to 4.61, marking a decrease of 0.50.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.78. This value exceeds the healthy maximum of 70. It has increased from 93.10 (Mar 24) to 93.78, marking an increase of 0.68.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.39. This value exceeds the healthy maximum of 70. It has increased from 94.89 (Mar 24) to 95.39, marking an increase of 0.50.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 20.10. This value is within the healthy range. It has decreased from 25.95 (Mar 24) to 20.10, marking a decrease of 5.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.12. This value is within the healthy range. It has decreased from 17.03 (Mar 24) to 12.12, marking a decrease of 4.91.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,137.76. It has increased from 1,087.33 (Mar 24) to 1,137.76, marking an increase of 50.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.41. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.41.
- For EV / EBITDA (X), as of Mar 25, the value is 6.97. This value is within the healthy range. It has increased from 6.06 (Mar 24) to 6.97, marking an increase of 0.91.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.53.
- For Retention Ratios (%), as of Mar 25, the value is 93.77. This value exceeds the healthy maximum of 70. It has increased from 93.09 (Mar 24) to 93.77, marking an increase of 0.68.
- For Price / BV (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.22 (Mar 24) to 1.18, marking a decrease of 0.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.53.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bliss GVS Pharma Ltd:
- Net Profit Margin: 11.14%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.84% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.02% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.12
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.08
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.6 (Industry average Stock P/E: 52.27)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.14%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 102, Hyde Park, Saki Vihar Road, Mumbai Maharashtra 400072 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Nandkumar K Chodankar | Chairman & Ind.Director |
| Mr. Gagan Harsh Sharma | Managing Director |
| Dr. Vibha Gagan Sharma | Whole Time Director |
| Mrs. Shruti Vishal Rao | Whole Time Director |
| Mr. Santosh L Parab | Independent Director |
| Ms. Shilpa Bhatia | Independent Woman Director |
FAQ
What is the intrinsic value of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd's intrinsic value (as of 17 January 2026) is ₹176.65 which is 2.70% higher the current market price of ₹172.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,821 Cr. market cap, FY2025-2026 high/low of ₹196/105, reserves of ₹1,122 Cr, and liabilities of ₹1,400 Cr.
What is the Market Cap of Bliss GVS Pharma Ltd?
The Market Cap of Bliss GVS Pharma Ltd is 1,821 Cr..
What is the current Stock Price of Bliss GVS Pharma Ltd as on 17 January 2026?
The current stock price of Bliss GVS Pharma Ltd as on 17 January 2026 is ₹172.
What is the High / Low of Bliss GVS Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bliss GVS Pharma Ltd stocks is ₹196/105.
What is the Stock P/E of Bliss GVS Pharma Ltd?
The Stock P/E of Bliss GVS Pharma Ltd is 16.6.
What is the Book Value of Bliss GVS Pharma Ltd?
The Book Value of Bliss GVS Pharma Ltd is 107.
What is the Dividend Yield of Bliss GVS Pharma Ltd?
The Dividend Yield of Bliss GVS Pharma Ltd is 0.29 %.
What is the ROCE of Bliss GVS Pharma Ltd?
The ROCE of Bliss GVS Pharma Ltd is 11.7 %.
What is the ROE of Bliss GVS Pharma Ltd?
The ROE of Bliss GVS Pharma Ltd is 8.36 %.
What is the Face Value of Bliss GVS Pharma Ltd?
The Face Value of Bliss GVS Pharma Ltd is 1.00.